Daptomycin (Cubicin®)是一種新型抗生素，用於治療腰椎骨髓炎，僅有少數案例報告，使用daptomycin的療程和劑量仍有待確立。本病例為一名腰椎骨髓炎methicillin-resistant Staphylococcus aureus（MRSA）感染且長期血液透析的糖尿病患者，在使用vancomycin治療失敗後轉而使用daptomycin治療。因糖尿病可能會影響傷口癒合，且血液透析也會影響daptomycin藥物動力學，目前臨床上沒有相似的報告，本文深入分析與探討其影響daptomycin療效的原因，包括療程、使用劑量、安全性等相關文獻，能提供醫療人員使用daptomycin治療腰椎MRSA感染之臨床經驗。此乃國內首次案例報告探討daptomycin用於難治療的抗藥性金黃色葡萄球菌感染腰椎骨髓炎。
 

Daptomycin is a cyclic lipopeptide antimicrobial agent that is used to treat severe infections caused by susceptible Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Daptomycin has received approval to treat complicated skin infection and infective endocarditis. A case has vertebral osteomyelitis caused by MRSA, diabetes mellitus, and end-stage renal disease undergoing hemodialysis. Daptomycin was given after the failure of vancomycin therapy. The efficacy, dosage, and safety of daptomycin for treating vertebral osteomyelitis caused by MRSA were evaluated. We expected the case can offer the experience of daptomycin in the treatment of patients with MRSA vertebral osteomyelitis.